Chandra Bhagat Pharma Ltd vs Onyx Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Chandra Bhagat Pharma Ltd is ₹ 33 as of 27 Apr 15:30 . The P/E Ratio of Chandra Bhagat Pharma Ltd changed from 158.4 on March 2021 to 45.9 on March 2025 . This represents a CAGR of -21.94% over 5 yearsThe P/E Ratio of Onyx Biotec Ltd changed from 21.3 on March 2025 to 21.3 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Chandra Bhagat Pharma Ltd changed from ₹ 29.88 crore on March 2021 to ₹ 39.48 crore on March 2025 . This represents a CAGR of 5.73% over 5 yearsThe Market Cap of Onyx Biotec Ltd changed from ₹ 105.17 crore on March 2025 to ₹ 105.17 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

FAQs for the comparison of Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd

Which company has a larger market capitalization, Chandra Bhagat Pharma Ltd or Onyx Biotec Ltd?

Market cap of Chandra Bhagat Pharma Ltd is 24 Cr while Market cap of Onyx Biotec Ltd is 59 Cr

What are the key factors driving the stock performance of Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd?

The stock performance of Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd?

As of May 4, 2026, the Chandra Bhagat Pharma Ltd stock price is INR ₹33.0. On the other hand, Onyx Biotec Ltd stock price is INR ₹33.0.

How do dividend payouts of Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd compare?

To compare the dividend payouts of Chandra Bhagat Pharma Ltd and Onyx Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.